Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents

Area of Science:

• Oncology
• Hepatology
• Pharmacology

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality globally.
• Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) represent significant therapeutic advancements in HCC management.
• Current research focuses on novel combinations and alternative pathway targets for HCC treatment.

Purpose of the Study:

• To review recent therapeutic advancements in Hepatocellular Carcinoma (HCC).
• To highlight the growing importance of tyrosine kinase inhibitors (TKIs) in HCC treatment strategies.
• To emphasize the need for expanded molecular testing and resistance monitoring in clinical practice.

Main Methods:

• Review of recent clinical trials and laboratory studies in HCC therapy.
• Analysis of the role of tyrosine kinase inhibitors (TKIs) in monotherapy and combination treatments.
• Evaluation of emerging targeted therapies and immune checkpoint inhibitors (ICIs).

Main Results:

• Tyrosine kinase inhibitors (TKIs) are increasingly integral to HCC treatment regimens.
• Combinations of TKIs with immune checkpoint inhibitors (ICIs) show promise.
• Phase II trials are exploring novel combinations and alternative mutation targets.

Conclusions:

• Tyrosine kinase inhibitors (TKIs) play a pivotal role in current HCC therapeutic strategies.
• Expanded molecular testing and monitoring for acquired resistance are crucial for effective HCC management.
• Further research is essential to bridge the gap between laboratory findings and clinical practice in HCC treatment.